Renato Dellamano, President and Founder of ValueVector, recently presented a speech at the Training Course organized by the Italian Society of Regulatory Affairs, Market Access and Pharmacovigilance (SIARV) in Rome on May 27-28, 2026 – https://www.siarv.it/giornate-di-studio-e-aggiornamento-dedicato-alle-attivita-regolatorie-di-accesso-e-di-farmacovigilanza-19-corso-didattico/
The title of his speech was: “Beyond the horizon: Pharmaceutical innovation between geopolitical storms and new cures’’. Key topics addressed were:
- The inequalities in access to innovative therapies, based on an analysis of the 2025 update of the EFPIA / IQVIA “W.A.I.T.” Indicator;
- Some challenges posed by the European Joint Clinical Assessment (JCA) procedure, given some potential conflicts between European and national HTA procedures;
- The evolving context for R&D / clinical research, characterized in particular by the exponential growth, in recent years, of the number of clinical trials conducted in China vs US / Europe and some new trends which might change the world of clinical research in the near future, like, for instance: the use of artificial intelligence (AI), the expansion of real-world evidence studies, and the expanded use of patient-reported outcomes;
- The growing international pressures, like, for instance, those which led to the recent arrangement on pharmaceutical pricing signed between the US and the UK.
If you’d like to discuss or comment on the above topics, please contact us at the following email address: valuebox@valuevector.com .
